Rezolute Completes Enrollment in Phase 3 Ersodetug Trial for Tumor Hyperinsulinism

Rezolute completed enrollment of 16 participants in its Phase 3 upLIFT trial of ersodetug for tumor hyperinsulinism. Topline results are expected in mid-December 2026. * Previously reported results showed seven of the first eight participants met the primary endpoint; all seven stopped intravenous glucose treatment. No drug-related safety findings have been reported in the study so far. The eighth participant died from cancer progression shortly after enrollment and was counted as a nonresponder. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief via (Ref. ID: 202610141605PRIMZONEFULLFEED9845915) on October 14, 2026, and is solely responsible for the information contained therein. (C)